Trial Profile
An Exploratory Study to Investigate the Immunomodulatory Activity of Various Dose Levels of Anti Programmed-Death-1 (PD-1) Antibody (BMS-936558) in Subjects With Metastatic Clear Cell Renal Cell Carcinoma (RCC)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Dec 2023
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary)
- Indications Renal cell carcinoma
- Focus Pharmacodynamics
- Acronyms CheckMate 009
- Sponsors Bristol-Myers Squibb
- 24 Oct 2023 Results assessing combined expression of MKI67, FOXC1 and PDL1 is a pan-tumor tissue-agnostic predictor of PD1/PDL1 inhibitor efficacy presented at the 48th European Society for Medical Oncology Congress
- 01 Aug 2023 Results by deriving data from JAVELIN Renal 101 and checkmate-009/010/025 and other studies; retrospectively analyzing the role of BAP1-score as a biologically and clinically significant predictor of immune microenvironment and the clinical benefits from ICI-based immunotherapies over angiogenic/mTOR inhibitors, demonstrating its potential utility in optimizing the personalized therapeutic strategies in patients with advanced ccRCC , published in the Cancer Immunology Immunotherapy
- 10 Apr 2021 Results of retrospectively constructed and validated Multi-Omics Responder Scores in multiple public cohorts presented at the 112th Annual Meeting of the American Association for Cancer Research